Microorganism and composition comprising same

Abstract

A novel Lactobacillus rhamnosus KBL2290 strain exhibits various activities such as improving intestinal flora, anti-inflammatory, and strengthening intestinal tight junctions. The strain may increase intestinal flora of Akkermansia genus, Lactobacillus genus, Ruminococcus genus or Prevotella genus, suppress an expression of interleukin 1-beta (IL-1B), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 12p40 (IL-12p40), interleukin 13 (IL-13), or interleukin 17A (IL-17A), suppresses an expression of chemokine ligand 2 (CCL2) or chemokine ligand 1 (CXCL1), suppress an expression of cyclooxygenase 2 (Cox-2) or nitric oxide synthase (iNOS), promote an expression of interleukin 10 (IL-10) or transforming growth factor-β (TGF-β), and increase an expression of Zo-1 or Occludin. A pharmaceutical composition including the strain may prevent or treat inflammatory bowel disease.

1 .  Lactobacillus rhamnosus  KBL2290 strain with the Access number of KCTC 14875BP. 
     
     
         2 . The strain according to  claim 1 , wherein the strain increases intestinal flora of  Akkermansia  genus,  Lactobacillus  genus,  Ruminococcus  genus or  Prevotella  genus. 
     
     
         3 . The strain according to  claim 1 , wherein the strain suppresses an expression of interleukin 1-beta (IL-1β), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 12p40 (IL-12p40), interleukin 13 (IL-13), or interleukin 17A (IL-17A). 
     
     
         4 . The strain according to  claim 3 , wherein the strain suppresses an expression of chemokine ligand 2 (CCL2) or chemokine ligand 1 (CXCL1). 
     
     
         5 . The strain according to  claim 3 , wherein the strain suppresses an expression of cyclooxygenase 2 (Cox-2) or nitric oxide synthase (iNOS). 
     
     
         6 . The strain according to  claim 3 , wherein the strain promotes an expression of interleukin 10 (IL-10) or transforming growth factor-β (TGF-β). 
     
     
         7 . The strain according to  claim 1 , wherein the strain increases an expression of Zo-1 or Occludin. 
     
     
         8 . A pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising the strain according to  claim 1 , a culture thereof or an extract of the strain. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , wherein the inflammatory bowel disease includes one or more inflammatory bowel diseases selected from the group consisting of acute enteritis, ulcerative colitis, Crohn's disease, celiac disease, collagenous colitis, leaky gut syndrome and pseudomembranous colitis. 
     
     
         10 . A pharmaceutical composition for preventing or treating functional gastrointestinal disorders, comprising the strain according to  claim 1 , a culture thereof or an extract of the strain. 
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein the functional gastrointestinal disorder includes one or more selected from the group consisting of irritable bowel syndrome, functional bloating, noncardiac chest pain, non-ulcer dyspepsia, and chronic constipation and diarrhea. 
     
     
         12 . A prebiotic composition, comprising the strain according to  claim 1 , a culture thereof or an extract of the strain. 
     
     
         13 . The prebiotic composition according to  claim 12 , wherein the composition is for improving intestinal flora of at least one of  Akkermansia  genus,  Lactobacillus  genus,  Ruminococcus  genus, or  Prevotella  genus